Nakhle Saba graduated from the Lebanese University in Beirut with an MD in 2005. He completed his residency in the Department of Internal Medicine at East Tennessee State University in Johnson City, TN and Tulane University in New Orleans, LA. In 2008, he started a research track training in Hematology and Medical Oncology at Tulane University, where he closely worked with Laura Levy, PhD on targeting the kinase PKCβ in B-cell Acute Lymphoblastic Leukemia and Diffuse Large B-cell Lymphoma. Dr. Saba joined the lab of Adrian Wiestner MD, PhD, in January 2012 at the National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH). His research at the NIH was focused on tumor biology and developing new therapeutic approaches for Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL). He is certified by the American Board of Internal Medicine for Internal Medicine, Hematology and Medical Oncology. Dr. Saba joined Tulane Faculty in August 2014 as an Assistant Professor of Medicine, and started a translational program in B-cell malignancies. He treats patients with various hematological malignancies with a focus on lymphoma and B-cell leukemia, and performs stem cell transplant. Dr. Saba’s research focuses B-cell malignancies, in particular on CLL and MCL biology, to identify novel therapeutic targets for these diseases.
Saba NS, Liu D, Herman SEM, Underbayev C, Tian X, Behrend D, Weniger M, Skarzynski M, Gyamfi J, Fontan L, Melnick A, Grant C, Roschewski M, Navarro A, Bea S, Dunleavy K, Pittaluga S, Wilson W, Wiestner A. Pathogenic Role of B-cell Receptor Signaling and Canonical NF-κB Activation in Mantle Cell Lymphoma. Blood Prepublished online April 28, 2016. doi:10.1182/blood-2015-11-681460.
Collins J, Safah H, Lobelle-Rich P, Whaley S, Campbell S, Saba N. Reduction in Cell Viability and in Homeobox Protein Levels Following In Vitro Exposure to Delta-Tocopherol in Acute Myeloid Leukemia. Nutr Cancer. 2016 doi: 10.1080/01635581.2016.1153672. [Epub ahead of print].
Bitar C, Farooqui MZ, Valdez J, Saba NS, Soto S, Bray A, Marti G, Wiestner A, Cowen EW. Hair and Nail Changes during Long-term Therapy with Ibrutinib for Chronic Lymphocytic Leukemia. JAMA Dermatol. 2016 doi: 10.1001/jamadermatol.2016.0225. [Epub ahead of print].
Lipsky AH, Farooqui MZ, Tian X, Martyr S, Cullinane AM, Nghiem K, Sun C, Valdez J, Niemann CU, Herman SE, Saba N, Soto S, Marti G, Uzel G, Holland SM, Lozier JN, Wiestner A. Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 2015; 100:1571-1578.
Saba NS, Angelova M, Lobelle-Rich P, Levy LS. Disruption of pre-B-cell receptor signaling jams the WNT/β-catenin pathway and induces cell death in B-cell acute lymphoblastic leukemia cell lines. Leuk Res. 2015. pii: S0145-2126(15)30355-6. doi: 10.1016/j.leukres.2015.08.002. [Epub ahead of print].
Farooqui M, Valdez J, Martyr S, Aue G, Saba N, Niemann C, Herman S, Tian X, Marti G, Soto S, Hughes T, Jones J, Lipsky A, Pittaluga S, Stetler-Stevenson M, Yuan C, Lee Y, Pedersen L, Geisler C, Calvo K, Arthur D, Maric I, Childs R, Young N, Wiestner A. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase II investigator initiated trial. Lancet Oncol. 2015; 16:169-176.
Saba N, Wiestner A. Do Mantle Cell Lymphoma have an Achilles Heel? Curr Opin Hematol. 2014; 21:350-357.
Herman S, Niemann C, Farooqui M, Jones J, Mustafa R, Lipsky A, Saba N, Martyr S, Soto S, Valdez J, Gyamfi J, Maric I, Calvo K, Pedersen LB, Geisler C, Liu D, Marti G, Aue G, Wiestner A. Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. Leukemia. 2014; 28:2188-2196.
Fiskus W*, Saba N*, Shen M, Ghias M, Liu J, DasGupta S, Chauhan L, Rao R, Gunewardena S, Schorno K, Austin C, Maddocks K, Byrd J, Melnick A, Huang P, Wiestner A, Bhalla K. Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia. Cancer Res. 2014; 74:2520-2532.
* WF and NS are co-first authors
Saba NS, Cao C, Saba JS, Janbain M, Maalouf B, Dang P, Safah H. Bortezomib in Plasmablastic Lymphoma, a Case Report and Review of the Literature. Onkologie. 2013; 36:287-291.
Saba NS, Levy LS. Protein kinase C-beta inhibition induces apoptosis and inhibits cell cycle progression in AIDS-related Non-Hodgkin lymphoma cells. J Investig Med. 2012; 60:29-38.
Blaya M, Saba N. Chemotherapy-Induced Hyperpigmentation of the Tongue. N Engl J Med. 2011; 365(10):e20.
Saba NS, Levy LS. Apoptotic induction in B-cell acute lymphoblastic leukemia cell lines treated with a protein kinase Cβ inhibitor. Leuk Lymphoma. 2011; 52:877-886.
Link to Dr. Saba's NCBI Bibliography: http://www.ncbi.nlm.nih.gov/sites/myncbi/1NakbGjI4HI5A/bibliography/47389108/public/?sort=date&direction=ascending